SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell CarcinomaUnusual Whales·Jul 17 at 07:27 AM688506-4.44%02615
China’s Biokin Soars After Its First-in-Class Cancer Drug Is Greenlit for Chinese Market LaunchYicai·Jun 23 at 01:26 AM688506-4.44%BMY+2.35%
15:07 ETSystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in Chinaprnewswire·Jun 22 at 02:09 PM688506-4.44%02615
